

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2023

On 21 March 2024, Dong-E-E-Jiao released its annual report for the year ended 31 December 2023.

Dong-E-E-Jiao Co., Ltd. (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Co, Ltd. (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 21 March 2024, Dong-E-E-Jiao released its annual report for the year ended 31 December 2023 (the “**Dong-E-E-Jiao Audited Annual Financials**”). Set out below are the key financial information of the Dong-E-E-Jiao Audited Annual Financials:

	As of 31 December 2023 <i>(RMB)</i> <i>(audited)</i>	As of 31 December 2022 <i>(RMB)</i> <i>(audited)</i>	Increase <i>(%)</i>
Total assets	13,306,306,533.41	12,631,382,359.34	5.34%
Net assets attributable to shareholders of the listed company	10,719,014,633.60	10,329,243,246.41	3.77%
	For the year ended 31 December		
	2023 <i>(RMB)</i> <i>(audited)</i>	2022 <i>(RMB)</i> <i>(audited)</i>	Increase/decrease <i>(%)</i>
Revenue	4,715,265,729.50	4,041,818,347.54	16.66%
Net profit attributable to the shareholders of the listed company	1,150,878,550.46	779,998,116.10	47.55%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	1,082,628,480.93	699,829,938.05	54.70%
Net cash flow from operating activities	1,953,438,009.50	2,144,878,185.39	-8.93%
Basic earnings per share <i>(RMB/share)</i>	1.79	1.21	47.93%
Diluted earnings per share <i>(RMB/share)</i>	1.79	1.21	47.93%
Weighted average return on net asset <i>(%)</i>	11.12%	7.68%	3.44 percentage points

As determined by the board of directors of Dong-E-E-Jiao, Dong-E-E-Jiao proposed to distribute a cash dividend of RMB17.8 (inclusive of tax) for every 10 shares to all shareholders of Dong-E-E-Jiao based on the total share capital of Dong-E-E-Jiao on the date of equity distribution registration. Such proposal shall be submitted for shareholders' approval at Dong-E-E-Jiao's 2023 annual general meeting.

The Dong-E-E-Jiao Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Dong-E-E-Jiao Audited Annual Financials, please refer to the annual report for the year ended 31 December 2023 published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 22 March 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.